NCT02477514

A Study to Evaluate the Effects of Tedizolid Phosphate on the Pharmacokinetics and Safety of Midazolam and Rosuvastatin (MK-1986-004)

A Multiple-Dose Study to Evaluate the Effects of Steady-State Tedizolid Phosphate Administration on the Pharmacokinetics and Safety of a Single Dose of Midazolam and Rosuvastatin

• Status: Completed
• Phase: Phase 1
• Study type: Interventional
• Enrollment: 18 (actual)
• Sponsor: Merck Sharp & Dohme LLC · Industry
• Sex: All
• Age: 19 Years – 55 Years
• Healthy volunteers: Accepted

Summary

The purpose of this study is to assess the effect of steady-state tedizolid phosphate on the single-dose pharmacokinetics of midazolam and rosuvastatin in healthy, adult participants.

Conditions

• Skin Diseases, Bacterial

Interventions

Type	Name	Description
DRUG	midazolam	2 mg (1 mL of 2 mg/mL oral syrup) administered as a single dose on Days 1 and 14
DRUG	rosuvastatin	10 mg tablet administered as a single oral dose on Days 3 and 16
DRUG	tedizolid phosphate	200 mg oral tablet administered once daily on Days 5-17

Timeline

• Start date: 2015-06-01
• Primary completion: 2015-08-01
• Completion: 2015-08-01
• First posted: 2015-06-22
• Last updated: 2015-08-24